Exelixis Inc vs Abbvie Inc.
EXEL vs ABBV — side-by-side comparison from reported financials. EXEL leads 5, ABBV leads 3 of 8 comparable metrics.
Exelixis Inc
EXEL · Healthcare
$60.62+2.71%Mixed
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
| Metric | EXEL | ABBV |
|---|---|---|
| Price | $60.62 | $276.43 |
| Market cap | $15.0B | $488B |
| Revenue (TTM) | $2.44B | $64.4B |
| Revenue growth | +12.9% | +1.8% |
| Net margin | 35.3% | 9.8% |
| Free cash flow | $1.17B | $18.2B |
| Net cash (debt) | — | ($56.2B) |
| 1-year price return | +57.2% | +19.8% |
| P/E | 17.2 | 77.4 |
| P/E vs own history (cheap-side %) | 81% | 23% |
| Dividend yield | — | 2.45% |
| Return on equity | 42% | 96% |
| Altman Z-score | — | 2.33 |
| CV checks passed | 9 of 10 | 9 of 10 |
| Employees | 1,077 | 57,000 |
Full résumé-style profiles: EXEL CV · ABBV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.